Form D · Biotechnology
Sound Pharmaceuticals Inc
Seattle, WA · CIK 0001165353
Offering snapshot reported Jun 6, 2018 · SEC filing
- Reported sold
- $8.41M Offering amount: $10.4M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 24, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 6, 2018 | Initial | $8,408,576 | No comparison | 5 | SEC filing |
| Sep 16, 2016 | Amendment | $4,100,000 | $3,800,000vs Aug 19, 2015 | 4 | SEC filing |
| Aug 19, 2015 | Initial | $300,000 | No comparison | 1 | SEC filing |
| Oct 16, 2013 | Amendment | $7,563,366 | No comparison | 21 | SEC filing |
| Dec 17, 2012 | Initial | $1,515,105 | No comparison | 9 | SEC filing |
| Dec 28, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 6, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-313998
The amounts above include the conversion of note principal and interest. Actual Total Offering Amount $10,408,575.34; Actual Total Amount Sold $8,408,575.34.
Series C-2 Preferred Stock
Source: Form D, filed Jun 6, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joseph Ashley | Director |
| David Guyer | Director |
| Glenn Kawasaki | Director |
| Jonathan Kil | Director, Executive |
| Eric Lynch | Director, Executive |
| James Paul Rickey | Executive |
| John Sullivan | Executive |
| Paul Thompson | Director |
| James C. Towne | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4010 Stone Way North, Suite 120
Seattle, WA, 98103
Seattle, WA, 98103